Autolus Therapeutics plc Amortization of Intangible Assets
Autolus Therapeutics plc (AUTL) reported Amortization of Intangible Assets of $500.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-11
- Autolus Therapeutics plc amortization of intangible assets for the quarter ending 2026-06-30 was $500.00K, a 66.67% increase year-over-year.
- Autolus Therapeutics plc amortization of intangible assets for the quarter ending 2026-03-31 was $490.00K, a 71.93% increase year-over-year.
- Autolus Therapeutics plc amortization of intangible assets for the quarter ending 2025-12-31 was $489.00K, a 201.85% increase year-over-year.
- Autolus Therapeutics plc amortization of intangible assets for the quarter ending 2025-09-30 was $500.00K.
- Autolus Therapeutics plc amortization of intangible assets for fiscal 2025 was $1.52M, a 837.04% increase from fiscal 2024.
- Autolus Therapeutics plc amortization of intangible assets for fiscal 2024 was $162.00K.
- Autolus Therapeutics plc amortization of intangible assets for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Autolus Therapeutics plc amortization of intangible assets for fiscal 2022 was $65.00K, a 27.78% decline from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $500.00K 10-Q · filed 2026-08-11 | $979.00K 10-Q · filed 2026-08-11 | $1.48M derived: sum of 3 quarters · filed 2026-08-11 | $1.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $490.00K 10-Q · filed 2026-05-14 | $979.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.48M derived: sum of 3 quarters · filed 2026-05-14 | $1.78M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $489.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $989.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.29M derived: sum of 3 quarters · filed 2026-08-11 | $1.52M 10-K · filed 2026-03-27 |
| 2025-09-30 | $500.00K 10-Q · filed 2025-11-12 | $800.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.03M 10-Q · filed 2025-11-12 | $1.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-11 | $570.00K 10-Q · filed 2026-08-11 | $747.00K derived: sum of 3 quarters · filed 2026-08-11 | $747.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $285.00K 10-Q · filed 2026-05-14 | $447.00K derived: sum of 2 quarters · filed 2026-05-14 | $447.00K derived: sum of 3 quarters · filed 2026-05-14 | $447.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $162.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $162.00K derived: sum of 2 quarters · filed 2026-03-27 | $162.00K derived: sum of 3 quarters · filed 2026-03-27 | $162.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 | |||
| 2022-12-31 | $65.00K 10-K · filed 2024-03-21 | |||
| 2021-12-31 | $90.00K 10-K · filed 2024-03-21 | |||
| 2020-12-31 | $91.00K 20-F · filed 2023-03-07 | |||
| 2019-12-31 | $47.00K 20-F · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |